Key facts
- This page summarizes Michael Halstead's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
- 6 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Mar 2024, 20:32.
Michael Halstead - 07 Mar 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)
- Reporting relationship
- EVP and General Counsel
- Issuer ticker
- ITCI
- Reported as of
- 07 Mar 2024
- Net transaction value
- -$1,353,235
- SEC form
- 4
- Accepted by SEC
- 11 Mar 2024, 20:32:14 UTC
- Prior SEC filing
- 08 Mar 2024
- Next SEC filing
- 14 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lawrence J. Hineline, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Halstead filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 11 Mar 2024.
Change
- Previous filing in this sequence was filed on 08 Mar 2024.
- Current net transaction value: -$1,353,235.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ITCI
transaction
Common Stock
Sale
- Transaction value
- $854,000
- Shares
- -12,912
- Change %
- -98%
- Price
- $66.14
- Shares after
- 220
- Date
- 07 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ITCI
transaction
Common Stock
Sale
- Transaction value
- $14,698
- Shares
- -220
- Change %
- -100%
- Price
- $66.81
- Shares after
- 0
- Date
- 07 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F3
ITCI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +7,345
- Change %
- Price
- Shares after
- 7,345
- Date
- 10 Mar 2024
- Ownership
- Direct
- Footnotes
- F4
ITCI
transaction
Common Stock
Sale
- Transaction value
- $401,963
- Shares
- -6,107
- Change %
- -83%
- Price
- $65.82
- Shares after
- 1,238
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F5
ITCI
transaction
Common Stock
Sale
- Transaction value
- $82,575
- Shares
- -1,238
- Change %
- -100%
- Price
- $66.70
- Shares after
- 0
- Date
- 11 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITCI
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -7,345
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 7,345
- Date
- 10 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,345
- Exercise price
- Footnotes
- F7, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
This sale was effected pursuant to a Rule 10b5-1 trading plan originally adopted by the reporting person on March 15, 2023 and amended on May 8, 2023 and August 11, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.69 to $66.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.7115 to $66.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F4
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.31 to $66.302, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 to $67.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Footnote F7
Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F8
On March 10, 2022, the reporting person was granted 22,034 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.